Regulatory action by US food and drug authorities has exposed serious contamination and record‑keeping failures at two Chinese manufacturers that supply key ingredients for compounded GLP‑1 medicines, raising fresh questions about the safety of unregulated weight‑loss drug copies reaching Western markets.
What inspectors found
Inspectors from the US Food and Drug Administration (FDA) reported black mould on equipment, "gross contamination" on floors and "significant insect activity" in ceilings at one facility, while documents at both sites suggested attempts to conceal lapses in quality control.
- Chengdu Shengnuo Biopharm Co. — FDA inspectors in August recorded staff running with laboratory documents and placing them in lockers, and observed personnel pouring product samples into sinks. The report noted black mould on equipment and extensive insect activity.
- Nanjing Chengong Pharmaceutical Co. — September inspections uncovered evidence of bogus documentation and that workers had been sourcing active ingredients from other factories.
Both companies were identified as manufacturers of semaglutide and tirzepatide, the active molecules in blockbuster medicines from Novo Nordisk and Eli Lilly. The ingredients were being produced for custom‑made, compounded versions of the drugs that are not approved by regulators and are not reviewed for safety or effectiveness.
Regulatory and public‑health implications
The FDA placed the two manufacturers on its import‑alert list, a measure that can prevent products from entering the US. The alerts follow a series of inspections and a Freedom of Information Act request that made the reports public. Observers say the findings underscore the risks posed by a fast‑growing market for compounded GLP‑1s, which are often sold more cheaply than branded medicines and supplied through complex international chains.
“The inspection findings suggest a serious accident waiting to happen,” said Michael Rogers, a principal at Canal Row Advisors and a former associate commissioner for inspections and investigations at the FDA.
That assessment will be of concern to clinicians and patients here in Wales and across the UK, where demand for GLP‑1 therapies has grown rapidly in recent years. Even though the specific FDA action targets imports into the United States, the global nature of pharmaceutical supply means materials produced in the same factories could be destined for compounding operations elsewhere.
What we know about the companies
| Company | Inspection month | Key issues noted |
|---|---|---|
| Chengdu Shengnuo Biopharm Co. | August | Black mould, filthy floors, insect activity, staff hiding documents, pouring samples down sinks |
| Nanjing Chengong Pharmaceutical Co. | September | Evidence of bogus documentation; sourcing ingredients from other factories |
Chengdu Shengnuo Biopharm is a subsidiary of Chengdu Shengnuo Biotec Co. In response to the findings, the parent company said in a regulatory filing in China that it had been "diligently implementing effective measures" to rectify the issues.
Local consequences and cautions for patients
For residents in Mold and across Wales, the story is a reminder that not all products marketed as GLP‑1 therapies are equivalent. Licensed medicines undergo stringent trials and regulatory review. By contrast, compounded drugs are mixed or altered for individual patients and may not be subject to the same oversight, especially when active ingredients are sourced internationally.
Pharmacists and prescribers should be vigilant about the provenance of ingredients used in compounded preparations. Patients considering unlicensed, compounded versions of GLP‑1 drugs should seek advice from their GP or a regulated pharmacy and weigh the potential risks of products whose manufacturing conditions are in question.
As demand for weight‑loss and diabetes medicines continues to rise, this episode highlights the need for robust supply‑chain transparency and international co‑operation between regulators to ensure that medicines reaching patients are produced in hygienic, well‑documented facilities.
